April 01, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra Kurla Complex,
Mumbai-400051

Symbol: OSELDEVICE

Sub: Press Release

Ref: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – FDA Registration of Manufacturing Facility

Dear Sir/Ma'am,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit Press Release titled on "***OSEL Devices Limited has successfully obtained registration from the United States Food and Drug Administration (FDA) for its hearing aid manufacturing facility located at Greater Noida, Uttar Pradesh, India.***"

Kindly take the above information on records and disseminate.

Thanking you,

Yours faithfully

For OSEL DEVICES LIMITED

Diksha
Digitally signed by Diksha
Date: 2026.04.01 18:23:35 +05'30'

Diksha
Company Secretary and Compliance Officer
M. No. A72889

Press Release

OSEL Devices Limited has successfully obtained registration from the United States Food and Drug Administration (FDA) for its hearing aid manufacturing facility located at Greater Noida, Uttar Pradesh, India.

New Delhi, April 01, 2026

OSEL Devices Limited is pleased to announce that its hearing aid manufacturing facility located at Greater Noida, Uttar Pradesh, India, has been successfully registered with the United States Food and Drug Administration (FDA).

The registration has been confirmed by the U.S. Department of Health and Human Services through the FDA's Center for Devices and Radiological Health (CDRH), and the facility has been duly listed in the FDA Registration and Device Listing Database.

Strategic Significance and Business Impact

This development represents a transformational milestone for the Company with significant value-accretive implications: -

Entry into a High-Value Market: The U.S. medical devices market, among the largest globally, is now directly accessible to the Company, unlocking substantial revenue potential.

Strong Revenue Upside: The Company expects this development to materially enhance its export capabilities and drive accelerated growth in its hearing aid segment over the medium term.

Margin Expansion Potential: Access to regulated markets such as the U.S. typically commands superior pricing, which is expected to positively impact operating margins.

Global Credibility & Competitive Positioning: FDA registration significantly strengthens the Company's brand equity, regulatory credibility, and competitive standing in international markets.

Platform for Scale & Partnerships: The Company is actively exploring strategic partnerships, OEM opportunities, and distribution alliances in the U.S. and other developed markets.

Export-Led Growth Strategy: This milestone aligns with the Company's strategic focus on expanding its global footprint and transitioning towards a higher share of export-driven revenues.

The Company believes that this achievement will serve as a key growth catalyst, strengthening its long-term business outlook and creating enhanced value for all stakeholders.

Diksha Digitally signed by Diksha Date: 2026.04.01 18:23:58 +05'30'

****